Kriya Materials

Year of investment: 2017

Kriya Materials is an innovative coatings company that focuses on high value coating formulations. It develops and manufactures its own tailor-made nanoparticles which form the basis for a wide range of coatings with unique, high-end properties.

Applications include displays, solar panels, window films and glasses.

Fortimedix Surgical

Year of investment: 2016

Fortimedix Surgical is a fast growing medical device company, aiming to challenge the status quo in minimally invasive surgery by creating novel devices that capture the claimed benefits of single-port surgery. The company is headquartered in Nuth, The Netherlands, and has a US subsidiary in San Diego, CA. With a strong history as a global market leader in contract stent manufacturing, Fortimedix has been a trusted partner in the medical device industry for over 15 years. Fortimedix Surgical is committed to driving the evolution of minimally invasive surgery through smart innovation across surgical specialties to improve the quality of life of patients throughout the world.

Enzypep

Year of investment: 2014

Enzypep developed a breakthrough technology for the synthesis of peptides using enzymes. The Enzypep technology is expected to become the state-of-the-art in design and preparation of complex peptides. Compared with standard synthesis it results in pharmaceutical products with a much higher purity, at a much lower cost and in a sustainable, environmentally-friendly manner.

BioActor

Year of investment: 2012

BioActor develops and markets proprietary health ingredients for use in functional foods, medical nutrition and dietary supplements.

BioActor focuses on the development of proprietary bioactives with human clinical evidence that address health concerns related to metabolic syndrome and ageing such as diabetes, osteoporosis and cardiovascular disease.

For more information on the company and product(s), please refer to the following video:

ACS Biomarker

Year of investment: 2011

ACS Biomarker targets discovery and validation of novel miRNA and protein-based cardiovascular biomarkers, improving diagnoses and management of cardiac diseases. ACS Biomarker licensed out exclusive rights to BG Medicine on its biomarker Galectin-3 as a prognostic indicator of congestive heart failure.

Q Chip

Year of investment: 2011

Q Chip, based in Cardiff (Wales, UK) commercializes innovative sustained-release drug formulations of injectable therapeutics. The sustained- release can be tailored and administration of the therapeutics is improved. The company was acquired by Midatech Pharma plc in late 2014.

Nano4Imaging

Year of investment: 2011

Nano4Imaging produces and uses medical devices and implants visible for medical interventions to monitor their function (e.g under MRI). N4I’s products MRWire and MagnaFy are used for navigation to treat cardiovascular diseases and for radiotherapy.

For more information on the company and product(s), please refer to the following video:

 

Ekompany Agro

Year of investment: 2011

Ekompany Agro is a manufacturer of controlled release fertilizers using a proprietary and patented process. The company operates a 60,000 ton/year name plate capacity coated fertilizer plant and integrated 150,000 ton blending plant in Born (Netherlands). The assets were acquired by Shandong Kingenta Ecological Engineering early 2016.

Cellmade

Year of investment: 2010

CellMade develops and commercializes cell biology products and services: human-origin primary cells, co-culture models, customized cell isolation and characterization. CellMade also invests in its own R&D program using its CellInsight platform for identification of targets and biomarkers related to inflammatory pathologies. The company has facilities in Marseille (France) and at the Chemelot Campus.

FABPulous

Year of investment: 2009

FABPulous develops a disposable device which allows for rapid semi-quantitative diagnostic testing in blood or plasma. The first application is for diagnosis of acute myocardial infarction, based on heart-type fatty acid binding protein (H-FABP) as a biomarker. This test is able to demonstrate, within 2-3 minutes after drawing a drop of blood by means of a finger prick, whether or not H-FABP is elevated, which is indicative of an acute myocardial infarction.